Evidence map›Paper›PMID 27065849›Full record

ArticleCase reports in oncology

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Corey A Carter, Bryan T Oronsky, Scott Z Caroen, Jan J Scicinski, Aiste Degesys, Michelle M Kim, Arnold L Oronsky, Harry Lybeck, Pedro Cabrales, Neil Oronsky and 3 more

Registry-linked trialOpen access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02489903 (A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02489903 phase2completednot on this map

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

TypeinterventionalSponsorEpicentRx, Inc.Ran2015 to 2021Enrolled139ConditionsSmall Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial CancerArmsRRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. RRx-001 protects against cisplatin-induced toxicities.Journal of cancer research and clinical oncology · 2017
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Corey A CarterWalter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
Bryan T OronskyEpicentRx Inc., Mountain View, Calif., USA.
Scott Z CaroenEpicentRx Inc., Mountain View, Calif., USA.
Jan J ScicinskiEpicentRx Inc., Mountain View, Calif., USA.
Aiste DegesysWalter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
Michelle M KimDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Mich., USA.
Arnold L OronskyInterWest Partners, Menlo Park, Calif., USA.
Harry LybeckDepartment of Physiology, University of Helsinki, Helsinki, Finland.
Pedro CabralesDepartment of Bioengineering, University of California San Diego, La Jolla, Calif, USA.
Neil OronskyCFLS Data, Mountain View, Calif., USA.
Tony ReidMoores Cancer Center, University of California San Diego, La Jolla, Calif., USA.
Joseph RoswarskiWalter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
Christina BrzezniakWalter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
Walter Reed National Military Medical Center · USEpicentre (South Africa) · ZAUniversity of California, San Diego · USUniversity of Helsinki · FIUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.

Indexed as

EpigeneticEpisensitizationPlatinum doubletsResensitizationResistanceSmall-cell lung cancer

Identifiers

PMID27065849
PMCPMC4821137
OpenAlexW2307621786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.